Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 15/20 | 0.46 |
| ▸ | HTR2B | P41595 | 15/20 | 0.46 |
| ▸ | HTR2A | P28223 | 14/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | MLNR | O43193 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19664799 | 0.98 | HTR2C (0.45) | HTR2CHTR2BHTR2ACYP3A4HTR7 | |
| Hydrochloric Acid SCHEMBL2910827 | 0.98 | HTR2C (0.45) | HTR2CHTR2BHTR2ACYP3A4HTR7 | |
| SCHEMBL17984881 | 0.85 | CYP1A2 (0.38) | HTR2CHTR2BHTR2ACYP2D6 | |
| SCHEMBL3236226 | 0.84 | CYP3A4 (0.57) | HTR2CHTR2BHTR2ACYP3A4 | |
| SCHEMBL19674741 | 0.84 | CYP3A4 (0.42) | HTR2CHTR2BHTR2ACYP3A4MLNR | |
| Hydrochloric Acid SCHEMBL19664944 | 0.83 | CYP3A4 (0.56) | HTR2CHTR2BHTR2ACYP3A4 | |
| SCHEMBL17984847 | 0.82 | CYP3A4 (0.47) | HTR2CHTR2BHTR2ACYP3A4HTR7 | |
| Hydrochloric Acid SCHEMBL2913654 | 0.82 | ASIC3 (0.46) | HTR2CHTR2BHTR2ACYP3A4 | |
| SCHEMBL17984843 | 0.80 | HTR2C (0.47) | HTR2CHTR2BHTR2ACYP3A4 | |
| SCHEMBL19674824 | 0.80 | KMO (0.40) | HTR2CHTR2BHTR2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227362-B2 | Anti-pulmonary tuberculosis nitroimidazole derivative | MEDSHINE DISCOVERY INC. (CN) | 2019-03-12 | — | — | US | disclosed |
| US-20180162878-A1 | ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE | MEDSHINE DISCOVERY INC. (CN) | 2018-06-14 | — | — | US | disclosed |
| US-20180162878-A1 | ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE | MEDSHINE DISCOVERY INC. (CN) | 2018-06-14 | — | — | US | disclosed |
| EP-3252059-A1 | ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE | Medshine Discovery Inc. (CN) | 2017-12-06 | — | — | EP | disclosed |
| WO-2016119706-A1 | ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE | 南京明德新药研发股份有限公司 | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162878-A1 | ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE | NDUFV1, NDUFV2, MT-ND4 | HTR2C 4132/4885HTR2B 4095/4885HTR2A 4312/4885 |
| US-10227362-B2 | Anti-pulmonary tuberculosis nitroimidazole derivative | NDUFV1, NDUFV2, MT-ND4 | HTR2C 4132/4885HTR2B 4095/4885HTR2A 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.